Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S1931||SWOG||Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GU007||NRG||Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I)||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-80702||CALGB||A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-49907||CALGB||A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens; Cyclophosphamide; Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC); Versus Capecitabine in Women 65 Years and Older with Node Positive or Node Negative Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|E5508||ECOG||Randomized Phase III Study of Maintenance Therapy with Bevacizumab; Pemetrexed; or a Combination of Bevacizumab and Pemetrexed Following Carboplatin; Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA6134||ECOG-ACRIN||DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-HN004||NRG||Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin||Adult CIRB - Late Phase Emphasis||Available to Open|
|E3200||ECOG||Phase III Trial of Bevacizumab (NSC 704865); Oxaliplatin (NSC 266046); Fluorouracil and Leucovorin versus Oxaliplatin; Fluorouracil and Leucovorin versus Bevacizumab Alone in Previously Treated Patients with Advanced Colorectal Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S1900A||SWOG||A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|C80405||CALGB||A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab; or Cetuximab (C225); or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum||Adult CIRB - Late Phase Emphasis||Available to Open|